GlassScriptPhysician profile
Ryan P Roop
NPI 1457541799
$2,180.19
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $362 · 2021: $16.80 · 2023: $49.73 · 2024: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328 · Education: $22.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.81 |
| Education | $22.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $332.82 | 2019-2023 | Sprycel |
| Histosonics, INC. | $301.07 | 2024 | |
| Merck Sharp & Dohme LLC | $284.10 | 2019-2020 | |
| Genentech USA, INC. | $248.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $213.76 | 2019-2020 | |
| Eisai INC. | $118.05 | 2019 | |
| Amgen INC. | $79.74 | 2019-2020 | |
| Janssen Biotech, INC. | $75.87 | 2019-2020 | |
| Incyte Corporation | $65.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $65.07 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $60.42 | 2019-2020 | |
| Clovis Oncology, INC. | $50.87 | 2019 | |
| Taiho Oncology, INC. | $43.81 | 2019-2023 | |
| Astellas Pharma US INC | $37.97 | 2019 | |
| Gilead Sciences, INC. | $35.92 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $34.43 | 2019 | |
| Foundation Medicine, INC. | $30.14 | 2019 | |
| Puma Biotechnology, INC. | $29.58 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $13.45 | 2019 | |
| Pfizer INC. | $12.36 | 2020 | |
| Celgene Corporation | $11.94 | 2020 | |
| Kite Pharma, INC. | $11.93 | 2020 | |
| Seagen INC. | $11.67 | 2020 | |
| Genzyme Corporation | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Roop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.